Mountain Valley MD Announces Transition of Chief Medical Officer to Advisory Role
Mountain Valley MD Announces Transition of Chief Medical Officer to Advisory Role
TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the "Company" or "MVMD") (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), an early-stage biotech business centered around the implementation, licensing and reselling of key technologies and formulations, today announced that Dr. Azhar Rana, the Company's Chief Medical Officer ("CMO"), will be transitioning to an advisory capacity effective February 1, 2023.
多倫多，2023年1月11日(環球通訊社)--山谷MD控股公司。(“公司“或”MVMD)(CSE：MVMD)(OTCQB：MVMDF)(法蘭克福機場市場代碼：200MP)是一家以關鍵技術和配方的實施、許可和轉售為中心的早期生物技術企業，該公司今天宣佈，公司首席醫療官Azhar Rana博士將從2023年2月1日起過渡到顧問職位。
As announced in its news release dated November 29, 2022 (the "Nov 29 PR"), the Company has been transitioning from a research and development phase to a commercialization focus. Subsequently and as a result, the Company is beginning to align its human capital decisions with a revenue-driven business plan based on the three lines of business described in the Nov 29 PR, focusing on recruiting experienced talent in those particular areas of human, plant, and husbandry animal health commercialization in the coming months.
正如在其日期為2022年11月29日的新聞稿(“11月29日公關”)中宣佈的那樣，公司已經從研發階段過渡到商業化重點。隨後，該公司開始將其人力資本決策與基於11月29日公關中描述的三個業務線的收入驅動型業務計劃保持一致，並在未來幾個月專注於招聘人類、植物和畜牧動物健康商業化這些特定領域的經驗豐富的人才。
Dr. Rana joined the Company as CMO in August of 2021 and has made numerous contributions to the organization's advancement toward its commercialization objectives during his tenure. Dr. Rana will continue to advise MVMD's management as needed pursuant to an advisory agreement.
拉納博士於2021年8月加入公司，擔任首席營銷官，在任職期間為公司實現商業化目標做出了許多貢獻。根據一項諮詢協議，拉納博士將根據需要繼續為MVMD的管理層提供建議。
"We are grateful to Dr. Rana for his contributions to MVMD and look forward to continuing to work together in his new advisory role as we progress through this next phase focused on our key projects and technologies and the generation of revenues with a view to and our overarching goal to create long-term shareholder value," said Dennis Hancock, President & CEO of Mountain Valley MD.
山谷MD首席執行官總裁和首席執行官丹尼斯·漢考克説：“我們感謝拉納博士對MVMD的貢獻，並期待着在我們下一階段繼續擔任他的新顧問角色時共同努力，把重點放在我們的關鍵項目和技術以及創造收入上，以期實現我們創造長期股東價值的總體目標。”
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
關於山谷MD控股公司
Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:
山谷MD正在打造一個以關鍵技術和配方的實施、許可和轉售為中心的世界級組織：
- patented Quicksome™ oral formulation and delivery technologies,
- patented Quicksol™ solubility formulation technology
- licensed product reseller of Agrarius™, a novel agricultural plant signalling technology
- 獲得專利的Quickome™口服配方和遞送技術，
- 獲得專利的Quicksol™溶解度配方技術
- 農業植物信號新技術--AGLARIUS™的特許產品經銷商
Consistent with its vision towards "More Life", MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.
與其“更多生活”的願景一致，MVMD將其擁有和授權的技術應用於其工作，為人類和畜牧動物應用提供先進的分子，包括開發用於疼痛控制、減肥、能量、注意力、睡眠、焦慮等的產品。此外，MVMD與agarius的合作重點是對作物產量產生積極影響，並減少化肥的使用。
MVMD's patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.
MVMD的專利Quickome™技術利用專利配方和穩定分子將活性成分封裝和配製成高效的產品格式。其結果是新一代產品配方能夠更快地將營養食品和藥物分子輸送到人體內，具有更大的影響力、效率和準確性。
MVMD's patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.
MVMD獲得專利的QUICKSOL™技術涵蓋了所有可有效應用於多種病毒應用的高度溶解的大環內酯類化合物，這些應用可能會對全球人類和動物健康產生積極影響。
MVMD's licensed Agrairus™ agricultural plant signalling technology that could be capable of application to agricultural crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.
MVMD獲得許可的Agrairus™農業植物信號技術能夠應用於農作物，以自然提高產量，減少化肥使用量，並增強對蟲害和氣候變化的一般適應能力。
For more Company information and contact details, visit .
SOURCE: Mountain Valley MD Holdings Inc.
欲瞭解更多公司信息和聯繫方式，請訪問。
資料來源：山谷MD控股公司。
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
關於前瞻性信息的警示聲明
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.
本新聞稿中包含的某些陳述可能構成前瞻性信息。前瞻性信息通常是通過使用諸如“預期”、“計劃”、“估計”、“預期”、“可能”、“將”、“打算”、“應該”等詞語來識別的，但並非總是如此。前瞻性信息涉及已知和未知的風險、不確定性和其他因素，可能導致實際結果或事件與前瞻性信息中預期的大不相同。
The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.
由於監管決定、公司所在行業的競爭因素、當前的經濟狀況和其他因素，公司的實際結果可能與這些前瞻性信息中預期的大不相同，其中許多因素不是公司可以控制的。
The Company is making forward-looking statements, including but not limited to: the Company's human capital decisions aligning with its three previously announced business lines; the transition of Dr. Rana's role from CMO to an advisor and the timing thereof.
該公司作出前瞻性陳述，包括但不限於： 該公司的人力資本決定與其先前宣佈的三個業務領域保持一致；拉納博士的角色從首席營銷官轉變為顧問以及這一轉變的時機。
The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
本公司認為，前瞻性信息中反映的預期是合理的，但不能保證這些預期將被證明是正確的，不應過度依賴此類前瞻性信息。本新聞稿中包含的任何前瞻性信息代表公司截至本新聞稿發佈之日的預期，在該日期之後可能會發生變化。除非適用的證券法規要求，否則公司不會因為新信息、未來事件或其他原因而更新或修改任何前瞻性信息，也不承擔任何義務。
Neither the CSE nor OTC has reviewed or approved the contents of this press release.
CSE和場外交易委員會都沒有審查或批准本新聞稿的內容。
CONTACT: For further information: Dennis Hancock President and Chief Executive Officer Mountain Valley MD Holdings Inc. Investor Relations @ 647-725-9755 Email: info@mvmd.com
欲瞭解更多信息，請聯繫：丹尼斯·漢考克·總裁兼硅谷MD控股公司首席執行官
譯文內容由第三人軟體翻譯。